64th ASH Annual Meeting & Exposition | 2022 | New Orleans, LA

Hodgkin lymphoma highlights at ASH 2022 and future outlooksПодробнее

Highlights at ASH 2022: the promise of T-cell redirecting therapies in multiple myelomaПодробнее

Exciting updates in R/R multiple myeloma: highlights at ASH 2022Подробнее

The importance of promoting minorities in hematologyПодробнее

CAR-HEMATOTOX risk stratification predicts hematological toxicity and infectious complicationsПодробнее

Addressing the potential role of immunotherapy in the frontline treatment of ALLПодробнее

High-risk AML: the 2022 ELN risk classification and challenges in this patient populationПодробнее

Exciting updates in higher-risk MDS at ASH 2022Подробнее

Myeloma highlights at ASH 2022: BiTEs, CAR-T therapy, novel targets, and moreПодробнее

Clinical trials aiming to reduce the toxicity of novel agents in AMLПодробнее

Christophe Willekens, MD: Reduced Venetoclax and Azacitidine in AMLПодробнее

Novel therapeutics in essential thrombocythemiaПодробнее

Highlights in PTCL at ASH 2022Подробнее

Highlights in Waldenström’s macroglobulinemia at ASH 2022Подробнее

Insights into novel agents and potential combination therapies being explored in MFПодробнее

CMML highlights from ASH 2022Подробнее

ASH 2022 LBA: Findings from the ALIFE2 trialПодробнее

CMRG 2022 Review of the 64th ASH Annual Meeting and ExpositionПодробнее

ASH 2022 LBA: post-transplant cyclophosphamide, tacrolimus & MMF for GvHD prophylaxis in RICПодробнее

Challenges with bringing novel immune therapies to MDSПодробнее